

Oncology Research

- Approved Study:** February 2026
A Phase III, Randomized, Double-blind, Placebo-controlled Study of LY4064809 Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2-Advanced Breast Cancer with a *PIK3CA* Mutation who Received No Prior Treatment for Advanced Breast Cancer (J6M-MC-JSGD)
- Investigators: Rana Usman, MD (PI); Amit Jain, MD; Paschal Wilson, MD
Summary: The purpose of this research is to learn more about the investigational drug LY4064809, a possible treatment for breast cancer.
- Approved Study:** November 2025
A Phase II, Double-blind, Placebo-controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-induced Nausea and Vomiting in Adult Participants with Malignant Disease (J2R-MC-YAAD)
- Investigators: Amit Jain, MD (PI); Rana Usman, MD; Paschal Wilson, MD;
Summary: The purpose of this study is to assess the safety and efficacy of the study drug in the prevention of chemotherapy-induced nausea and vomiting compared to a placebo.
- Approved Study:** April 2025
SUNRAY – A Global Pivotal Study in Participants with *KRAS* G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab versus Placebo and Pembrolizumab in those with PD-L1 Expression \geq 50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum versus Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)
- Investigators: Amit Jain, MD (PI); Usman Khan, MD; Jiahuai Tan, MD; Paschal Wilson, MD
Summary: The purpose of this study is to determine if adding olomorasib to standard of care treatment helps to control symptoms better and for a longer period of time in non-small cell lung cancer patients.
- Approved Study:** February 2024
An Observational Study Profiling Advanced Stage Breast Cancer Patients to Screen for Investigational Therapies
- Investigator: Paschal Wilson, MD (PI); Amit Jain, MD; Usman Khan, MD; Jiahuai Tan, MD
Summary: The purpose of this in-house project is to match patients to relevant investigational therapies.

Approved:

February 2023

Study:

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients (MTG-022)

Investigators:

Paschal Wilson, MD (PI); Hematology and Oncology Group

Summary:

This study project involves minimal risk blood draw protocols.